| Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF A Koski, L Kangasniemi, S Escutenaire, S Pesonen, V Cerullo, I Diaconu, ... Molecular Therapy 18 (10), 1874-1884, 2010 | 204 | 2010 |
| Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients V Cerullo, S Pesonen, I Diaconu, S Escutenaire, PT Arstila, M Ugolini, ... Cancer research 70 (11), 4297-4309, 2010 | 200 | 2010 |
| Ischemic Neoangiogenesis Enhanced by β2-Adrenergic Receptor Overexpression: A Novel Role for the Endothelial Adrenergic System G Iaccarino, M Ciccarelli, D Sorriento, G Galasso, A Campanile, G Santulli, ... Circulation research 97 (11), 1182-1189, 2005 | 183 | 2005 |
| Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors N Nishio, I Diaconu, H Liu, V Cerullo, I Caruana, V Hoyos, ... Cancer research 74 (18), 5195-5205, 2014 | 161 | 2014 |
| Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors V Cerullo, MP Seiler, V Mane, N Brunetti-Pierri, C Clarke, TK Bertin, ... Molecular Therapy 15 (2), 378-385, 2007 | 154 | 2007 |
| Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus I Diaconu, V Cerullo, MLM Hirvinen, S Escutenaire, M Ugolini, ... Cancer research 72 (9), 2327-2338, 2012 | 145 | 2012 |
| Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus V Cerullo, I Diaconu, L Kangasniemi, M Rajecki, S Escutenaire, A Koski, ... Molecular Therapy 19 (9), 1737-1746, 2011 | 140 | 2011 |
| PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile MA Croyle, HT Le, KD Linse, V Cerullo, G Toietta, A Beaudet, L Pastore Gene therapy 12 (7), 579-587, 2005 | 135 | 2005 |
| Antiviral and antitumor T-cell immunity in patients treated with GM-CSF–coding oncolytic adenovirus A Kanerva, P Nokisalmi, I Diaconu, A Koski, V Cerullo, I Liikanen, ... Clinical Cancer Research 19 (10), 2734-2744, 2013 | 125 | 2013 |
| Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients S Pesonen, I Diaconu, L Kangasniemi, T Ranki, A Kanerva, SK Pesonen, ... Cancer research 72 (7), 1621-1631, 2012 | 123 | 2012 |
| Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients I Liikanen, L Ahtiainen, MLM Hirvinen, S Bramante, V Cerullo, ... Molecular Therapy 21 (6), 1212-1223, 2013 | 122 | 2013 |
| Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 JD Dias, O Hemminki, I Diaconu, M Hirvinen, A Bonetti, K Guse, ... Gene therapy 19 (10), 988-998, 2012 | 106 | 2012 |
| Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin CE Wang, H Zhou, JR McGuire, V Cerullo, B Lee, SH Li, XJ Li The Journal of cell biology 181 (5), 803-816, 2008 | 104 | 2008 |
| Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors P Nokisalmi, S Pesonen, S Escutenaire, M Särkioja, M Raki, V Cerullo, ... Clinical Cancer Research 16 (11), 3035-3043, 2010 | 101 | 2010 |
| Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors S Pesonen, I Diaconu, V Cerullo, S Escutenaire, M Raki, L Kangasniemi, ... International journal of cancer 130 (8), 1937-1947, 2012 | 99 | 2012 |
| Oncolytic vaccinia virus for the treatment of cancer K Guse, V Cerullo, A Hemminki Expert opinion on biological therapy 11 (5), 595-608, 2011 | 88 | 2011 |
| AKT participates in endothelial dysfunction in hypertension G Iaccarino, M Ciccarelli, D Sorriento, E Cipolletta, V Cerullo, GL Iovino, ... Circulation 109 (21), 2587-2593, 2004 | 81 | 2004 |
| Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors S Pesonen, P Nokisalmi, S Escutenaire, M Särkioja, M Raki, V Cerullo, ... Gene therapy 17 (7), 892-904, 2010 | 80 | 2010 |
| An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance V Cerullo, I Diaconu, V Romano, M Hirvinen, M Ugolini, S Escutenaire, ... Molecular Therapy 20 (11), 2076-2086, 2012 | 77 | 2012 |
| Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects MP Seiler, V Cerullo, B Lee Current gene therapy 7 (5), 297-305, 2007 | 75 | 2007 |
Lucio PastoreProfessore di Biochimica Clinica e Biologia Molecolare Clinica, Università di Napoli "Federico II"Dirección de correo verificada de ceinge.unina.it
